Balancing patient value and payer cost in hematologic malignancies: can it be done?

Click to increase image sizeClick to decrease image size

Declaration of interest

CR Flowers discloses being a Consultant: Abbvie, Bayer, Celgene (unpaid), Genentech/Roche (unpaid), Gilead, OptumRx, Spectrum. Research Funding for this Work: Burroughs Wellcome Fund, National Cancer Institute. Other Research Funding: Abbvie, Celgene, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, TG Therapeutics, Eastem Cooperative Oncology Group, National Cancer Institute, V Foundation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. A reviewer on this manuscript has disclosed they are a shareholder of Pharmerit, a HEOR consulting form, which receives funding from a large number of pharmaceutical companies.

Additional information

Funding

This paper was funded by the Burroughs Wellcome Fund, NCI K24CA208132.